戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uropean Registry of Transcatheter Repair for Tricuspid Regurgitation).
2 om restrictive myocardial disease and severe tricuspid regurgitation.
3 res of RV size and function, or magnitude of tricuspid regurgitation.
4 ading to further annular dilatation and more tricuspid regurgitation.
5 rwent tricuspid valve replacement for severe tricuspid regurgitation.
6 ight-sided filling pressures, and functional tricuspid regurgitation.
7 he right ventricle (RV) and right atrium and tricuspid regurgitation.
8  RV compression did not induce or exacerbate tricuspid regurgitation.
9 riven by less frequent progression to severe tricuspid regurgitation.
10 e in adult patients with severe, symptomatic tricuspid regurgitation.
11  dimension >7 cm, home oxygen use, or severe tricuspid regurgitation.
12 ht ventricular dilation and dysfunction, and tricuspid regurgitation.
13 easures in patients with severe, symptomatic tricuspid regurgitation.
14 reatment of patients with symptomatic severe tricuspid regurgitation.
15 ent implantation for the treatment of severe tricuspid regurgitation.
16  tricuspid valve repair system, for reducing tricuspid regurgitation.
17 or severe lung disease, dialysis, and severe tricuspid regurgitation.
18 on because of progressive RV dysfunction and tricuspid regurgitation.
19 nscatheter tricuspid valve repair for severe tricuspid regurgitation.
20 ificantly associated with mortality, but not tricuspid regurgitation.
21 om restrictive myocardial disease and severe tricuspid regurgitation.
22 upper body flushing (70%), asthma (38%), and tricuspid regurgitation (23%).
23 ive patients with severe isolated functional tricuspid regurgitation (33 centres, 10 countries), surv
24 60% vs. 4%, p < 0.0001), moderate or greater tricuspid regurgitation (4% vs. 0%, p = 0.06), and aorti
25 d severe atrial dilatation (5 cases), mitral/tricuspid regurgitation (5), atrial mural thrombus (3),
26 %] versus 0 [0%] versus 0 [0%], P=0.012) and tricuspid regurgitation (6 [46%] versus 1 [8%] versus 2
27 HD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation, 817 had aortic regurgitation, 4
28                             Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype
29                                  (PASCAL for Tricuspid Regurgitation-a European registry [PASTE]; NCT
30                        The PASTE (PASCAL for Tricuspid Regurgitation-a European registry) study is an
31 nferior outcomes in the presence of residual tricuspid regurgitation after cardiac surgery, surgical
32 ith restrictive myocardial disease or severe tricuspid regurgitation after constrictive pericarditis
33   Importantly, moderate or severe mitral and tricuspid regurgitation also decreased (33.7% vs. 8.6% [
34 ic function and RV-PA coupling and increased tricuspid regurgitation and Eed as compared to patients
35  accounts for 10%-15% of clinically relevant tricuspid regurgitation and has better outcomes compared
36 ibrillator were more likely to develop >mild tricuspid regurgitation and larger structural and functi
37 r ICD leads may result in severe symptomatic tricuspid regurgitation and may not be overtly visualize
38 oppler echocardiography variables (including tricuspid regurgitation and pulmonary regurgitation) and
39  with recognition of the risk of progressive tricuspid regurgitation and right heart failure in patie
40  late outcomes because of the progression of tricuspid regurgitation and right heart failure.
41                                              Tricuspid regurgitation and RV function did not change b
42                      In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricus
43                              The severity of tricuspid regurgitation and safety were also assessed.
44  patients with moderate or lesser degrees of tricuspid regurgitation and tricuspid annular dilatation
45 eroidal shape was associated with >=moderate tricuspid regurgitation and tricuspid annular dilation.
46 ic pressure >=50 mmHg and moderate to severe tricuspid regurgitation) and their impact on post-operat
47 ar remodeling, greater coexisting mitral and tricuspid regurgitation, and a higher prevalence of left
48 in combination with right heart failure, and tricuspid regurgitation; and (iii) a typical histopathol
49 weight (n=472), adjusting for sex, syndrome, tricuspid regurgitation, arch obstruction, and shunt typ
50 ntation if preoperative RV pressure load and tricuspid regurgitation are also considered.
51 owever, many patients with unoperated severe tricuspid regurgitation are also deemed at very high or
52                               RV failure and tricuspid regurgitation are common.
53                          Most operations for tricuspid regurgitation are done at the time of left-sid
54 id valve replacement in patients with severe tricuspid regurgitation are poorly understood.
55 cations for tricuspid valve surgery to treat tricuspid regurgitation are related to the cause of the
56                     Mitral regurgitation and tricuspid regurgitation are the most common valvular hea
57 nction, are independent of RV-PA coupling or tricuspid regurgitation, are associated with exercise-in
58 ntricular systolic dysfunction > or =3+, and tricuspid regurgitation area > or =1.8 cm2).
59 ictive ring annuloplasty repair of secondary tricuspid regurgitation at the time of left-sided valve
60      Increased recognition and correction of tricuspid regurgitation at the time of surgery is increa
61                            Atrial functional tricuspid regurgitation (atrial TR) has received growing
62 appears to be safe and effective at reducing tricuspid regurgitation by at least one grade.
63 2011, to August 28, 2013) and had measurable tricuspid regurgitation by spectral Doppler.
64  for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or t
65       Tricuspid valve replacement for severe tricuspid regurgitation can be performed with an accepta
66                                       Severe tricuspid regurgitation caused by a PPM or ICD lead is a
67 derwent tricuspid valve operation for severe tricuspid regurgitation caused by previously placed PPM
68  PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation [CLASP TR] Early Feasibility Stu
69  PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation [CLASP TR] Early Feasibility Stu
70  right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF.
71 lines recommend a more proactive approach to tricuspid regurgitation correction and highlight the shi
72  pulmonary artery pressure assessed from the tricuspid regurgitation derived maximal pressure gradien
73 me ratio, ejection fraction, and severity of tricuspid regurgitation did not differ by shunt type.
74                                       First, tricuspid regurgitation does not simply go away after co
75                          Changes observed in tricuspid regurgitation Doppler echocardiographic variab
76 actor for mortality in patients with chronic tricuspid regurgitation due to acquired heart disease.
77                 One patient developed severe tricuspid regurgitation due to entrapment of the anterio
78 during jugular venous examination and severe tricuspid regurgitation during transthoracic ECG.
79                                     Overall, tricuspid regurgitation estimated systolic pressure grad
80 terest in the treatment of severe functional tricuspid regurgitation (FTR) due to the awareness of it
81 t of the etiology and severity of functional tricuspid regurgitation (FTR) has many limitations, espe
82                                   Functional tricuspid regurgitation (FTR) is an important clinical e
83                                   Functional tricuspid regurgitation (FTR) is common in heart failure
84 ated with left heart pathologies, functional tricuspid regurgitation (FTR) is often left untreated du
85                                   Functional tricuspid regurgitation (FTR) with structurally normal v
86 d predictive for RV failure in patients with tricuspid regurgitation grade >2 and pulmonary arterial
87 tricular diastolic area (17 to 18.7 cm2) and tricuspid regurgitation grade (2 + to 3 +; p < 0.0001 be
88  After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly.
89           We advocate the measurement of the tricuspid regurgitation gradient, pulmonary regurgitatio
90 ad >=2 severe native VHDs (left-sided and/or tricuspid regurgitation, Group C).
91 asive parameter was associated with residual tricuspid regurgitation &gt;=3+.
92 Patients with a moderate or severe degree of tricuspid regurgitation (&gt; or =2+) demonstrated by color
93 n multivariable analysis, moderate or severe tricuspid regurgitation (hazard ratio [HR], 26.537; 95%
94 renal replacement therapy, severe preimplant tricuspid regurgitation, history of cardiac surgery, and
95                   Conclusions In significant tricuspid regurgitation, impaired RV free wall longitudi
96 ER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compare
97 , right heart failure and moderate-to-severe tricuspid regurgitation in 5/6 CRS type II patients.
98 ssigned 400 patients with severe symptomatic tricuspid regurgitation in a 2:1 ratio to undergo either
99  anomaly is the most common cause of primary tricuspid regurgitation in adults with congenital heart
100  medically managed patients with >= moderate tricuspid regurgitation in Europe and North America (n =
101           Whether the surgical correction of tricuspid regurgitation in left heart disease can defini
102 nd function in all subjects, as well as mild tricuspid regurgitation in nine subjects, with normal es
103 es have begun to emerge for the treatment of tricuspid regurgitation in such patients.
104 tanding of the natural history of functional tricuspid regurgitation in the setting of left heart dis
105           PURPOSE OF REVIEW: The presence of tricuspid regurgitation in the setting of right ventricu
106 rain in patients with significant functional tricuspid regurgitation, in comparison with tricuspid an
107 sed and the percentage of moderate or severe tricuspid regurgitation increased from baseline to 1 yea
108 ghting the effectiveness of TTVR in reducing tricuspid regurgitation, inducing reverse right ventricu
109                                       Severe tricuspid regurgitation is a debilitating condition that
110                                              Tricuspid regurgitation is a frequent echocardiographic
111                                              Tricuspid regurgitation is a prevalent disease associate
112                           Second, functional tricuspid regurgitation is a progressive disorder charac
113                                           AF-tricuspid regurgitation is also discussed.
114                                       Severe tricuspid regurgitation is associated with disabling sym
115                                       Severe tricuspid regurgitation is associated with increased mor
116                                              Tricuspid regurgitation is associated with increased rat
117                                       Severe tricuspid regurgitation is associated with poor prognosi
118      Whereas tricuspid stenosis is uncommon, tricuspid regurgitation is frequently encountered and is
119                                       Marked tricuspid regurgitation is frequently present in patient
120 unction and stiffness associations with ECV, tricuspid regurgitation jet velocity (TRV) and exercise
121 high risks of reoperative surgery for severe tricuspid regurgitation late after left-sided valve surg
122 ght ventricular dysfunction, moderate-severe tricuspid regurgitation, low cardiac index, and raised r
123 ogistic regression models revealed that only tricuspid regurgitation, LV ejection fraction and 3D RV
124                                              Tricuspid regurgitation maximal velocity greater than 2.
125                                              Tricuspid regurgitation maximal velocity pressure gradie
126           Worsening systemic RV function and tricuspid regurgitation may develop after LVOT TPVR.
127                                   Decreasing tricuspid regurgitation may reduce symptoms and improve
128            Echodensities and moderate/severe tricuspid regurgitation merit attention as early signs o
129                   Non-invasive assessment of tricuspid regurgitation must define its cause and severi
130                              The severity of tricuspid regurgitation, myocardial performance index, p
131 evere right ventricular (RV) dysfunction and tricuspid regurgitation (n = 110, 31 events) and uncommo
132 n in those with mild/less RV dysfunction and tricuspid regurgitation (n = 181, 13 events, P < .001).
133  System in Patients With Moderate or Greater Tricuspid Regurgitation]; n=85) is an international, pro
134                             Atrial secondary tricuspid regurgitation occurs most commonly in elderly
135                                  Progressive tricuspid regurgitation occurs with age and is associate
136 p and 4.8% of those in the control group had tricuspid regurgitation of no greater than moderate seve
137 ividuals with plasma endothelin-1 levels and tricuspid regurgitation on echocardiogram (n = 3223) at
138  was limited to participants with detectable tricuspid regurgitation on echocardiography.
139 -valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitat
140 ades from baseline or the presence of severe tricuspid regurgitation, or death.
141 atation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitat
142 ncidence of preoperative acidosis (P:=0.02), tricuspid regurgitation (P:=0.001), and ventricular dysf
143 ation) and in spontaneous restoration of SR (tricuspid regurgitation) (P < 0.05).
144 rvational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott
145 rvational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott
146 rvational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott
147 rvational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott
148  functional status and no impact on residual tricuspid regurgitation, patients with higher mean pulmo
149 ease in E/e'(lat) (P=0.045), and decrease in tricuspid regurgitation peak velocity (P=0.024) than pat
150 ges in Doppler echocardiographically derived tricuspid regurgitation peak velocity and velocity durat
151 f lead-related (as distinct from functional) tricuspid regurgitation pose unique challenges.
152                                              Tricuspid regurgitation preceded third-degree block in 1
153                         Patients with severe tricuspid regurgitation present late and are often ineli
154 al velocity greater than 2.82 m/s as well as tricuspid regurgitation pressure gradient greater than 3
155 end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurg
156 hreshold (r=0.426; P=0.048), the severity of tricuspid regurgitation (r=0.692; P=0.009), tricuspid va
157 moderate (2 patients) or severe (6 patients) tricuspid regurgitation recorded at either initial or re
158 se (aortic/mitral stenosis or regurgitation, tricuspid regurgitation), reduced ejection fraction <50%
159 nt analysis and correlated with RV function, tricuspid regurgitation, remnant left ventricular morpho
160                                             (TrIcuspid Regurgitation RePAIr With CaRdioband Transcath
161 R in 30 patients enrolled in the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcath
162 cal events comprised death, vascular events, tricuspid regurgitation requiring surgery, worsening hea
163 l haemodynamic abnormalities (more than mild tricuspid regurgitation, residual ventricular septal def
164                                          The tricuspid regurgitation resulting from this disease has
165 ocardiographic measurements (>mild degree of tricuspid regurgitation, RV outflow tract diameter in pa
166 interval, 1.2-3.3; P=0.0053]) and preimplant tricuspid regurgitation severity (odds ratio=2.9 [95% co
167                               T-TEER reduces tricuspid regurgitation severity and improves a composit
168 primary efficacy endpoint was a reduction in tricuspid regurgitation severity by at least one grade a
169 7.2 [-19.3, -15.8]%; P<0.001) raise, whereas tricuspid regurgitation severity improved only in transp
170                                              Tricuspid regurgitation severity was reduced by at least
171                                              Tricuspid regurgitation severity was the most important
172 id TEER appeared safe, significantly reduced tricuspid regurgitation severity, and decreased rates of
173  better LV and RV function, lower mitral and tricuspid regurgitation severity, were using smaller dos
174 ea, right ventricular systolic pressure, and tricuspid regurgitation severity.
175 for years, because of the misconception that tricuspid regurgitation should disappear once the primar
176 ctively (p < 0.0001); mean percent change in tricuspid regurgitation signal duration was 18% +/- 2% a
177 lyzing Doppler echocardiographically derived tricuspid regurgitation signals and that this informatio
178 lyzing Doppler echocardiographically derived tricuspid regurgitation signals during respiration in re
179 ulmonary hypertension or moderate or greater tricuspid regurgitation (stage 3), and significant right
180                                    Secondary tricuspid regurgitation (STR) in heart failure with pres
181                      Functional or secondary tricuspid regurgitation (STR) is the most frequent etiol
182 o describe the pathophysiology of functional tricuspid regurgitation, summarize the current reports f
183 ctively (p < 0.0001); mean percent change in tricuspid regurgitation time velocity integral was 27% +
184 ound In patients with significant functional tricuspid regurgitation, timely detection of right ventr
185 olic dimension and volume index, >= moderate tricuspid regurgitation (TR) (7%, 35%, and 53%, respecti
186  12.5%, persistent or new moderate or severe tricuspid regurgitation (TR) 20.8%, and new atrial fibri
187 ation of mechanisms of recurrent or residual tricuspid regurgitation (TR) after annuloplasty is neces
188 udy was to examine mortality associated with tricuspid regurgitation (TR) after controlling for left
189 e is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead placement.
190        We compared the predictive ability of tricuspid regurgitation (TR) and end-diastolic pulmonary
191 atheter edge-to-edge repair (T-TEER) reduced tricuspid regurgitation (TR) and improved health status
192 despite the known association between severe tricuspid regurgitation (TR) and mortality.
193 association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients un
194                                              Tricuspid regurgitation (TR) and right ventricular (RV)
195 cal and medical treatment options for severe tricuspid regurgitation (TR) are limited, and additional
196             Incidence and types of secondary tricuspid regurgitation (TR) are not well defined in atr
197                             A new grading of tricuspid regurgitation (TR) beyond severe has been prop
198 face for native leaflet coaptation to reduce tricuspid regurgitation (TR) by occupying the regurgitan
199                                   Benefit of tricuspid regurgitation (TR) correction and timing of in
200 and EDT lengthened (by 43 ms and 46 ms), and tricuspid regurgitation (TR) decreased (by 26 mm Hg, p <
201 ndergoing upright invasive exercise testing, tricuspid regurgitation (TR) Doppler estimates and invas
202                                       Severe tricuspid regurgitation (TR) exhibits high 1-year morbid
203                         Patients with severe tricuspid regurgitation (TR) frequently present with exe
204 y, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of mu
205 theter edge-to-edge repair (TEER) for severe tricuspid regurgitation (TR) has shown promise as an alt
206                          The determinants of tricuspid regurgitation (TR) hemodynamic severity remain
207                       Patients with isolated tricuspid regurgitation (TR) in the absence of left-side
208                                              Tricuspid regurgitation (TR) is a common and important c
209                                              Tricuspid regurgitation (TR) is a risk factor for mortal
210                                              Tricuspid regurgitation (TR) is an important predictor o
211          In hypoplastic left heart syndrome, tricuspid regurgitation (TR) is associated with circulat
212              Surgical management of isolated tricuspid regurgitation (TR) is associated with high mor
213                                       Severe tricuspid regurgitation (TR) is associated with high mor
214                                              Tricuspid regurgitation (TR) is common among adults with
215                                   Functional tricuspid regurgitation (TR) is increasingly recognized
216 implantable electronic device (CIED)-related tricuspid regurgitation (TR) is increasingly recognized
217                                       Severe tricuspid regurgitation (TR) is known to be associated w
218                                       Severe tricuspid regurgitation (TR) is known to be associated w
219  (FTR) has many limitations, especially when tricuspid regurgitation (TR) is more than severe.
220                       Accurate assessment of tricuspid regurgitation (TR) is necessary for identifica
221                      Functional or secondary tricuspid regurgitation (TR) is the most common cause of
222 o 8.4, p < 0.001), even after adjustment for tricuspid regurgitation (TR) jet velocity.
223 ed for only 10% to 20% of the variability in tricuspid regurgitation (TR) jet velocity.
224                                  Significant tricuspid regurgitation (TR) late after left heart valve
225                              The presence of tricuspid regurgitation (TR) may affect prognosis in pat
226                                              Tricuspid regurgitation (TR) occurs mainly from tricuspi
227                         However, significant tricuspid regurgitation (TR) often accompanies left-side
228                                       Severe tricuspid regurgitation (TR) often causes substantial im
229                                The impact of tricuspid regurgitation (TR) on cardiac remodeling has n
230  left heart syndrome who develop significant tricuspid regurgitation (TR) or require tricuspid valve
231 comitant tricuspid annuloplasty for moderate tricuspid regurgitation (TR) or tricuspid annular dilati
232                                     Isolated tricuspid regurgitation (TR) remains a management dilemm
233 atification in aortic (AR), mitral (MR), and tricuspid regurgitation (TR) remains a significant clini
234 sided cardiac lesions, associated functional tricuspid regurgitation (TR) that was surgically ignored
235 c magnetic resonance (CMR) quantification of tricuspid regurgitation (TR) to identify high-risk patie
236 clinical benefits for patients with >=severe tricuspid regurgitation (TR) treated with the EVOQUE tra
237 ct of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tr
238                                   Functional tricuspid regurgitation (TR) with a structurally normal
239 ught to evaluate the effect of PTE on severe tricuspid regurgitation (TR) without tricuspid annulopla
240                    Respiratory dependence of tricuspid regurgitation (TR), a long-held concept sugges
241 on (PR), 71 with multivalve disease, 73 with tricuspid regurgitation (TR), and 40 with aortic regurgi
242 rVHDs), including mitral regurgitation (MR), tricuspid regurgitation (TR), and aortic regurgitation (
243 milar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions freque
244 een shown to be highly effective in reducing tricuspid regurgitation (TR), and interest in this thera
245        For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcath
246 stood that annular dilatation contributes to tricuspid regurgitation (TR), other factors are less cle
247 ients with significant (moderate and severe) tricuspid regurgitation (TR), the decision to intervene
248 ) annuloplasty is recommended for functional tricuspid regurgitation (TR), which is caused by TV annu
249 thy subjects and in patients with functional tricuspid regurgitation (TR).
250 derate, and 69 severe PR; 55 had significant tricuspid regurgitation (TR).
251 h inadequate continuous wave (CW) signals of tricuspid regurgitation (TR).
252 ing color Doppler as an index of severity of tricuspid regurgitation (TR).
253  clinical implications of TVP with regard to tricuspid regurgitation (TR).
254 e primary endpoint and in-hospital worsening tricuspid regurgitation (TR).
255 ed, controlled study of patients with severe tricuspid regurgitation (TR).
256 licate the tricuspid annulus (TA) and reduce tricuspid regurgitation (TR).
257 94; 95% CI, 0.89-0.99; P=0.027), and </=mild tricuspid regurgitation (TR; HR, 3.58; 95% CI, 2.04-6.30
258                     For patients with severe tricuspid regurgitation, transcatheter tricuspid-valve r
259 ty System for Symptomatic Chronic Functional Tricuspid Regurgitation) trial is a prospective, single-
260                                Correction of tricuspid regurgitation using tricuspid transcatheter ed
261  was significantly higher in the groups with tricuspid regurgitation velocity >/=2.7 m/s.
262 ion mediated 19%-35%), E/e' ratio (18%-29%), tricuspid regurgitation velocity (27%-41%), and tricuspi
263 er pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per
264 .0001), LV lateral E/e' ratio (P=0.014), and tricuspid regurgitation velocity (P=0.019) were independ
265 with sickle cell disease (SCD), an increased tricuspid regurgitation velocity (TRV) by Doppler echoca
266 pants underwent echocardiography; those with tricuspid regurgitation velocity 2.5 m/s proceeded to ri
267  F were independently associated with higher tricuspid regurgitation velocity after adjustment for de
268 ystolic pressure (PASP) was derived from the tricuspid regurgitation velocity and PH defined as PASP
269 molysis (P < or = .002) but no difference in tricuspid regurgitation velocity compared with those not
270      Mean (+/- SD) percent change in maximal tricuspid regurgitation velocity was 13% +/- 6% and -8%
271 abnormal parameters (medial e', medial E/e', tricuspid regurgitation velocity, and left atrial volume
272                                              Tricuspid regurgitation velocity, which reflects systoli
273 with established clinical risk factors using tricuspid regurgitation velocity, white blood cell count
274 t between RV and right atrium (DeltaPRV-RA), tricuspid regurgitation velocity-time integral, and pulm
275 e independently associated with an increased tricuspid regurgitation velocity.
276                   PASP was measured from the tricuspid regurgitation velocity.
277 increased mitral E velocity, E/e' ratio, and tricuspid regurgitation velocity; and worse right ventri
278 icular tachycardia and sudden death, whereas tricuspid regurgitation was for those with atrial flutte
279                        Massive or torrential tricuspid regurgitation was found in 6.8% of patients in
280                       During surgery, severe tricuspid regurgitation was found to be caused by the PP
281                                              Tricuspid regurgitation was graded using a five-class gr
282 ome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated wit
283      The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA
284                                              Tricuspid regurgitation was massive (46 mL) (Figs 1-4).
285                             Moderate or less tricuspid regurgitation was present in 84% at 2 years in
286      Worsening of systemic RV dysfunction or tricuspid regurgitation was seen in 12 patients (57%) an
287  Analysis of right ventricular adaptation to tricuspid regurgitation was studied in 10 heart transpla
288 cular enlargement, systolic dysfunction, and tricuspid regurgitation were all associated with the pri
289 ars; 67% female) with severe or higher grade tricuspid regurgitation were analyzed.
290 s [62-78 years]) with significant functional tricuspid regurgitation were divided according to the pr
291             Patients with symptomatic severe tricuspid regurgitation were enrolled at 65 centers in t
292 id valve edge-to-edge repair for significant tricuspid regurgitation were included.
293 tal of 572 patients with severe, symptomatic tricuspid regurgitation were randomized to either tricus
294 out CP (restrictive cardiomyopathy or severe tricuspid regurgitation) were identified.
295                  The presence of significant tricuspid regurgitation, whether in the context of mitra
296 ation; inclusions bias related to detectable tricuspid regurgitation, which may limit generalizabilit
297 ht ventricular systolic function and greater tricuspid regurgitation, which persisted at 1 year.
298 ermore, patients with significant preimplant tricuspid regurgitation who did not receive a TVP experi
299 , abnormal septal curvature, and significant tricuspid regurgitation with a high regurgitant velocity
300 (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the

 
Page Top